PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.04
Negative P/E while Biotechnology median is -4.70. Seth Klarman would scrutinize path to profitability versus peers.
5628.35
P/S exceeding 1.5x Biotechnology median of 11.47. Jim Chanos would check for potential multiple compression risks.
1.76
P/B 50-90% of Biotechnology median of 3.09. Mohnish Pabrai would examine if this discount presents opportunity.
-25.62
Negative FCF while Biotechnology median P/FCF is -25.05. Seth Klarman would investigate cash flow improvement potential.
-25.62
Negative operating cash flow while Biotechnology median P/OCF is -25.34. Seth Klarman would investigate operational improvement potential.
1.76
Fair value ratio 50-90% of Biotechnology median of 3.10. Mohnish Pabrai would examine if this gap presents opportunity.
-6.19%
Negative earnings while Biotechnology median yield is -3.24%. Seth Klarman would investigate path to profitability.
-3.90%
Negative FCF while Biotechnology median yield is -2.62%. Seth Klarman would investigate cash flow improvement potential.